CRINETICS PHARMACEUTICALS IN (CRNX) Stock Balance Sheet
NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 94.57M | 264.55M | 54.90M | 32.70M | 200.70M | |||
| Marketable Securities | 1.18B | 1.09B | 503.66M | 301.80M | 133.00M | |||
| Receivables | 7.22M | 8.39M | 9.10M | 2.30M | 1.50M | |||
| Other Current Assets | 9.71M | 12.93M | 6.50M | 8.50M | 9.50M | |||
| Total Current Assets | 1.29B | 1.38B | 574.15M | 345.20M | 344.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 55.32M | 55.58M | 57.43M | 5.00M | 4.70M | |||
| Investments And Advances | N/A | 0.00 | 470.00K | 0.00 | 1.00M | |||
| Other Non-Current Assets | 14.95M | 3.63M | 3.30M | 2.00M | 600.00K | |||
| Total Non-Current Assets | 70.27M | 59.20M | 61.20M | 7.00M | 6.30M | |||
| TOTAL ASSETS | 1.36B | 1.43B | 635.35M | 352.20M | 351.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 45.26M | 51.66M | 35.34M | 18.60M | 7.50M | |||
| Accounts Payable | 9.84M | 5.85M | 6.55M | 6.90M | 8.50M | |||
| Other Current Liabilities | 2.21M | 2.18M | 2.06M | 2.20M | N/A | |||
| Total Current Liabilities | 57.31M | 59.68M | 43.94M | 27.70M | 16.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 50.02M | 50.10M | 52.30M | 8.10M | 3.10M | |||
| Total Non-Current Liabilities | 50.02M | 50.10M | 52.30M | 8.10M | 3.10M | |||
| TOTAL LIABILITIES | 107.33M | 109.79M | 96.25M | 35.80M | 19.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.05B | -952.11M | -653.70M | -439.20M | -275.30M | |||
| Additional Paid In Capital | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 2.30B | 2.28B | 1.19B | 759.40M | 607.60M | |||
| Other Shareholders' Equity | 2.00M | 963.00K | 977.00K | -3.90M | -400.00K | |||
| Shares Outstanding | 93.53M | 92.93M | 68.17M | 53.90M | 47.60M | |||
| Tangible Book Value per Share | 13.41 | 14.26 | 7.91 | 5.87 | 6.97 | |||
| Total Shareholders' Equity | 1.25B | 1.32B | 539.11M | 316.30M | 331.90M | |||
| TOTAL LIABILITIES AND EQUITY | 1.36B | 1.43B | 635.35M | 352.20M | 351.00M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 22.53 | 23.04 | 13.07 | 12.46 | 21.54 | |||
| Return On Assets (ROA) | -24.11% | -20.80% | -33.77% | -46.54% | -30.67% | |||
| Return On Equity (ROE) | -26.18% | -22.52% | -39.79% | -51.82% | -32.43% | |||
All data in USD , ROIC based on taxRate of 0.21